February 19th, the daily limit is known early: Seven major benefits are expected to ferment
For stocks, please read Jin Qilin analyst research report, authoritative, professional, timely, and comprehensive, to help you tap potential potential opportunities!
Sina Finance News on February 18 news, there are seven major benefits that may affect tomorrow’s stock market, specifically: Yang Jie Technology: signed a strategic cooperation agreement with SMIC Corporation Yang Jie Technology (300373) announced on the evening of February 18, the company 14Japan and SMIC Manufacturing (Shaoxing) Co., Ltd. reached a strategic cooperation agreement to carry out in-depth cooperation in the R & D and production of 8-inch high-end MOS and IGBT.
According to the agreement, Yangjie Technology is the purchaser, with an average annual production of not less than 2000 pieces / month; as a supplier, SMEC ensures that it provides capacity support for Yangjie Technology, with an average annual production capacity of not less than 合肥夜网 2000 pieces / month.
The agreement is valid for 3 years.
The implementation of the agreement will help the company to expand and enhance new businesses such as MOS and IGBT.
Rongsheng Development: In 2019, it achieved a net profit of more than 9.1 billion yuan, a year-on-year increase of 20%. Rongsheng Development (002146) disclosed the performance report in the evening of February 18, and the company achieved operating income of 709 in 2019.
5.3 billion, an annual increase of 25.
88%; net profit 91.
2 billion, an annual increase of 20.
32%; yield 2.
With the expansion of the company’s real estate business, the number of billable items has increased, and the settlement income has increased.
Zuoli Pharmaceutical: On-site inspection of the raw material Wuling bacteria powder through GMP. Zuoli 淡水桑拿网 Pharmaceutical (300181) announced on the evening of February 18 that the company’s raw material medicine (Wulin powder) passed the GMP on-site inspection. This time, it passed the GMP on-site inspection.The production line is a new production line of the company ‘s non-public offering of stock raising project “400 tons of Wuling fungus powder production line construction project”. This production line passed the GMP on-site inspection of the drug, which is conducive to improving the production capacity and production efficiency of Wuling fungus powder raw materials.
Huangshan Capsule: plans to acquire hilly hill material layout, bacterial virus protection and other fields Huangshan capsule (002817) announced on the evening of February 18 that the company proposed to acquire 100% of the distribution of hilly hill material in cash to rely on hilly hill material in bacterial virus protection, diagnosis and treatmentDisinfection products and other fields have gained competitive advantages in technology and products, and extended and expanded the company’s product service fields.
The two parties to the transaction have signed the Equity Acquisition Framework Agreement, and the transaction is not expected to constitute a major asset reorganization.
Karen shares: 2019 annual profit growth of 84% Karen shares (300715) on the evening of February 18 disclosed the performance report, the company’s total operating income in 2019 was 10.
4.1 billion, an annual increase of 68.
10%; net profit 1.
2 billion yuan, an annual increase of 84.
05%; basic profit income is 0.
At the core of the report, the company actively develops group procurement and transportation, municipal and other infrastructure construction projects for large real estate developers, and has achieved significant success.
Weiye: Winning the bid for the Chengdu Tianfu International Airport fine decoration project Weiye (300621) announced on the evening of February 18th that the company recently received a bid notification and confirmed it as the 14th bid for the Chengdu Tianfu International Airport terminal decoration projectThe successful bidders for the segment projects total about 1.
100 million yuan, construction period 424 days.
Haichen Pharmaceutical: Application for the registration of a platelet saban tablets was supplemented. Haichen Pharmaceutical (300584) announced on the evening of February 18 that the company recently received the notice of cancellation of the registration of a platelet saban tablets.
Aplatin saban tablets are mainly used for adult patients undergoing hip or knee replacement surgery to prevent venous thromboembolism.
The supplementary application for the registration of opioid saban tablets indicates that the company has made new progress in the research and development of cardiovascular and cerebrovascular products.